Expression of costimulatory molecule cd28 on t cells in human immunodeficiency virus type 1 infection: Functional and clinical correlations

Journal of Infectious Diseases

Volumn 169, Issue 4, 1994, Pages 730-738

  Brinchmann, Jan E ^a,b   Dobloug, Jan H ^a,b   Heger, Bernt H ^a,b   Haaheim, Lise L ^a,b   Sannes, Mette ^a,b   Egeland, Torstein ^a,b  

^a Institute of Transplantation Immunology National Hospital ^*  (Norway)

^b ULLEVÅL UNIVERSITY HOSPITAL   (Norway)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIGEN P24; CD28 ANTIGEN; CD3 ANTIGEN; CD4 ANTIGEN; CD8 ANTIGEN; HUMAN IMMUNODEFICIENCY VIRUS ANTIBODY; INTERLEUKIN 2; T LYMPHOCYTE RECEPTOR;

ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; ENZYME LINKED IMMUNOSORBENT ASSAY; FLOW CYTOMETRY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LYMPHOCYTE PROLIFERATION; MAJOR CLINICAL STUDY; PHENOTYPE; PRIORITY JOURNAL; SEROLOGY; T LYMPHOCYTE;

ANTIGENS, CD28; ANTIGENS, CD4; ANTIGENS, CD8; CASE-CONTROL STUDIES; CD4-CD8 RATIO; CD4-POSITIVE T-LYMPHOCYTES; CROSS-SECTIONAL STUDIES; FLOW CYTOMETRY; HIV INFECTIONS; HIV-1; HUMAN; INTERLEUKIN-2; LYMPHOCYTE ACTIVATION; SUPPORT, NON-U.S. GOV'T; T-LYMPHOCYTES; T-LYMPHOCYTES, SUPPRESSOR-EFFECTOR;

EID: 0028203633     PISSN: 00221899     EISSN: 15376613     Source Type: Journal    
DOI: 10.1093/infdis/169.4.730     Document Type: Article

References (37)

1. Centers for Disease Control. Revision of the CDC surveillance case definition for acquired immunodeficiency syndrome. MMWR 1987;36:1S-15S.
2. Fahey JL, Taylor JMG, Detels R, et al. The prognostic value of cellular and serologic markers in infection with human immunodeficiency virus type 1. N Engl J Med 1990;322:166-72.
3. Phillips AN, Lee C, Elford J, et al. Serial CD4 lymphocyte counts and development of AIDS. Lancet 1991;337:389-92.
4. Brinchmann JE, Vartdal F, Thorsby E. T lymphocyte subset changes in human immunodeficiency virus infection. J Acquir Immune Defic Syndr 1989;2:398-403.
5. Yagi MJ, Joesten ME. Wallace J. Roboz JP, Bekesi JG. Human immunodeficiency virus type 1 (HIV-1) genomic sequences and distinct changes in CD8+ lymphocytes precede detectable levels of HIV-1 antibodies in high-risk homosexuals. J Infect Dis 1991;164:183-8.
6. Walker BD, Plata F. Cytotoxic T lymphocytes against HIV. AIDS 1990;4:177-84.
7. Brinchmann JE, Gaudernack G, Vartdal F. CD8+ T cells inhibit HIV replication in naturally infected CD4+ T cells. Evidence fora soluble inhibitor. J Immunol 1990;144:2961-6.
8. Lane HC, Depper JM, Greene WC, Whalen G, Waldman TA, Fauci AS. Qualitative analysis of immune function in patients with the acquired immunodeficiency syndrome. N Engl J Med 1985;313:79-84.
9. Clerici M, Stocks NI, Zajac RA, et al. Detection of three distinct patterns of T helper cell dysfunction in asymptomatic, human immunodeficiency virus-seropositive patients. J Clin Invest 1989:84:18929.
10. Gruters RA, Terpstra FG, De Jong R. Van Noesel CJM, Van Lier RAW, Miedema F. Selective loss of T cell functions in different stages of HIV infection. Eur J Immunol 1990;20:1039-44.
11. Marrack P. Kappler J. The staphylococcal enterotoxins and their relatives. Science 1990;248:705-11.
12. Choi Y, Kotzin B. Herron L, Callahan L, Marrack P. Kappler J. Interaction of staphylococcus aureus toxin “superantigens” with human T cells. Proc Natl Acad Sci USA 1989;86:8941-5.
13. Centers for Disease Control. Classification system for human T-lym-photropic virus type III/lymphadenopathy-associated virus infections. MMWR 1986;35:334-9.
14. Centers for Disease Control. Guidelines for the performance of CD4+ T-cell determinations in persons with human immunodeficiency virus infection. MMWR 1992;41:1-17.
15. Funderud S, Nustad K, Lea T, et al. Fractionation of lymphocytes by immunomagnetic beads. In: Klaus GGB. ed. Lymphocytes: A practical approach. Washington, DC: IRL Press, 1987:55-65.
16. Vartdal F, Gaudemack G, Funderud S, et al. HLA class I and II typing using cells positively selected from blood by immunomagnetic isolation—a fast and reliable technique. Tissue Antigens 1986;28:301-12.
17. Gillis S, Ferm MM, Ou W, Smith KA. T cell growth factor: Parameters of production and a quantitative microassay for activity. J Immunol 1978:120:2027-32.
18. June CH, Ledbetter JA, Linsley PS, Thompson CB. Role of the CD28 receptor in T-cell activation. Immunol Today 1990:11:21 1-6.
19. Schwartz RH. Costimulation of T lymphocytes: The role of CD28, CTLA-4. and B7/BB1 in interleukin-2 production and immunotherapy. Cell 1992;71:1065-8.
20. Marrack P, Kappler J. The T cell receptor. Science 1987:238:1073-9.
21. Taniguchi T, Minami Y. The IL-2/IL-2 receptor system: A current overview. Cell 1993;73:5-8.
22. Fraser JD, Irving BA, Crabtree GR, Weiss A. Regulation of the interleukin-2 gene enhancer activity by the T cell accessory molecule CD28. Science 1991;251:313-6.
23. Damle NK, Mohagheghpour N, Hansen JA, Engleman EG. Alloanti-gen-specific cytotoxic and suppressor T lymphocytes are derived from phenotypically distinct precursors. J Immunol 1983; 131: 2296-300.
24. Levy JA. HIV pathogenesis and long-term survival [abstract PS-05-2]. In: Program and abstracts: IX International Conference on AIDS/IV STD World Congress (Berlin). London: Wellcome Foundation, 1993.
25. Mackewicz CE, Ortega HW, Levy JA. CD8+ cell anti-HIV activity correlates with the clinical state of the infected individual. J Clin Invest 1991;87:1462-6.
26. Pantaleo G, Koenig S, Baseler M, Lane HC, Fauci AS. Defective clono-genic potential of CD8+ T lymphocytes in patients with AIDS. J Immunol 1990:144:1696-704.
27. Ho HN, Hultin I.E, Mitsuyasu RT, et al. Circulating HIV-specific CD8+ cytotoxic T cells express CD38 and HLA DR antigens. J Immunol 1993;150:3070-9.
28. Ho DD, Moudgil T, Alam M. Quantitation of human immunodeficiency virus type 1 in the blood of infected persons. N Engl J Med 1989;321:1621-5.
29. Rosenberg ZF, Fauci AS. The immunopathogenesis of HIV infection. Adv Im munol 1989;47:377-431.
30. Langhoff E, McElrath J, Bos HJ, et al. Most CD4+ T cells from human immunodeficiency virus-1-infected patients can undergo prolonged clonal expansion. J Clin Invest 1989;84:1637-43.
31. Azuma M, Phillips JH, Lanier LL. CD28- T lymphocytes. Antigenic and functional properties. J Immunol 1993; 150:1147-59.
32. Clerici M, Roilides E, Via CS, Pizzo PA, Shearer GM. A factor from CD8+ T cells of human immunodeficiency virus-infected patients suppress HLA self-restricted T helper cell responses. Proc Natl Acad Sci USA 1992;89:8424-8.
33. Joly P, Guillon JM, Mayaud C, et al. Cell-mediated suppression of HIV-specific cytotoxic T lymphocytes. J Immunol 1989; 143:2193-201.
34. Amadori A, Chieco-Bianchi L. B cell activation and HIV-1 infection: Deeds and misdeeds. Immunol Today 1990;11:374-9.
35. Akbar AN, Terry L, Timms A, Beverly PCL, Janossy G. Loss ofCD45R and gain of UCHL-I reactivity is a feature of primed T cells. J Immunol 1988;140:2171-8.
36. Aboulker JP, Swart AM. Preliminary analysis of the Concorde trial. Lancet 1993;341:889-90.
37. Morishita Y, Sao H, Hansen JA, Martin PJ. A distinct subset of human CD4+ cells with a limited alloreactive T cell receptor repertoire. J Immunol 1989;143:2783-9.